Cradle, today announced that argenx is expanding use of Cradle's end-to-end AI-driven protein engineering platform to more scientists and antibody discovery programs following successful results from its initial work.
argenx is a Hold with its $550M Unnatural Products deal for an unproven pipeline that may pressure commercial products and R&D. Read more on ARGX stock here.
Investing.com -- Argenx SE announced Monday it will acquire biotech firm Unnatural Products for $550 million upfront plus contingent value rights tied to development and regulatory milestones, bringing the total potential value to approximately $1.15 billion.
Tipranks Press Release.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Argenx's (ARGX) Vyvgart sales beat expectations in Q3, with investors focused on upcoming multifocal
Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech.
The company beat sales expectations for its biggest moneymaker.
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient improvements observed as early as Week 4 and sustained through 52 weeksLate-breaking oral presentation on Wednesday, November 11th, 9:15 – 9:30 AM ET October 19, 2026, 8:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, toda
Cummins, Argenx and PACCAR offer potential buying opportunities after recent pullbacks, backed by strong earnings growth, improving forecasts and long-term business drivers.
October 15, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx
Tipranks Press Release.
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.